Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

IBL Finance IPO Date, Review, Price, Allotment Details

By Jagat Joshi
January 16, 2024

IBL Finance IPO Details: IBL Finance IPO date is fixed, The IPO will open on January 9 and will close on January 11. IBL Finance is a NSE SME IPO to raise ₹34.30 crores via IPO. The IBL Finance IPO price band is fixed at ₹51 with a market lot of 2000 shares.

IBL Finance commenced their lending business to self-employed professional and small business entrepreneurs during the financial year on March 31, 2019. Subsequently, from the Fiscal 2020, they migrated to a fintech-based financial services platform. As a technology-driven fintech company, they leverage technology and data science to make lending quick and easy. From mobile Apps, they provide instant personal loans which is almost 100% digital process. They launched a personal loans business to fulfill the needs of the underserved Indian population. Their digital personal loan offering is well-suited to address the needs of the growing digitally connected Indians.

The company launched a mobile-based personal loans business under the “IBL: Instant Personal Loan” brand. Under their personal loan lending business, they extend instant personal loans up to ₹50,000 with tenors of up to 12 months through an entirely digital mobile App-only process. Since their launch and up to March 31, 2023, they have disbursed 1,63,282 personal loans amounting to ₹7,105.44 lakhs. As of March 31, 2023, their personal loan business had an AUM of ₹1461.18 lakhs and they disbursed 1,22,078 personal loans amounting to ₹5234.70 lakhs, with an average ticket size of approx. ₹4500. The average tenor of loans which is outstanding at the end of Fiscal 2023 is 5 months.

The company revenue from operations for the Fiscal 2023, Fiscal 2022, and Fiscal 2021 was ₹1330.52 lakhs, ₹327.08 lakhs, and ₹ 112.59 lakhs, respectively. The profit before tax for the Fiscal 2023, Fiscal 2022, and Fiscal 2021 was ₹274.52 lakhs, ₹56.53 lakhs, and ₹(9.27) lakhs, respectively. The profit for Fiscal 2023, Fiscal 2022, and Fiscal 2021 was ₹192.83 lakhs, ₹42.73 lakhs, and ₹(9.88) lakhs, respectively.

Objects of the Issue:

Augmenting the company’s Tier-I capital base to meet the company’s future capital requirements, arising out of the growth of the business and asset; and
General corporate purposes.

IBL Finance IPO Review

Avoid

IBL Finance IPO Date & Price Band Details

IPO Open:	January 9, 2024
IPO Close:	January 11, 2024
IPO Size:	Approx ₹34.30 Crores, 6,725,000 Equity Shares
Face Value:	₹10 Per Equity Share
IPO Price Band:	₹51 Per Equity Share
IPO Listing on:	NSE SME
Retail Quota:	50% of the net offer
NII Quota:	50% of the net offer
DRHP Draft Prospectus:	Click Here
RHP Draft Prospectus:	Click Here

IBL Finance IPO Market Lot

The IBL Finance IPO minimum market lot is 2000 shares with a ₹102,000 application amount.

Application	Lot Size	Shares	Amount
Retail Minimum	1	2000	₹102,000
Retail Maximum	1	2000	₹102,000
S-HNI Minimum	2	4000	₹204,000

IBL Finance IPO Dates

The IBL Finance IPO date is January 9 and the IPO close date is January 11. The IPO allotment date is January 12 and the IPO might list on January 16.

IPO Open Date:	January 9, 2024
IPO Close Date:	January 11, 2024
Basis of Allotment:	January 12, 2024
Refunds:	January 15, 2024
Credit to Demat Account:	January 15, 2024
IPO Listing Date:	January 16, 2024

You can check IPO subscription status and IPO allotment status on their respective pages.

IBL Finance IPO Form

How to apply IBL Finance IPO? You can apply IBL Finance IPO via ASBA available in your bank account. Just go to the online bank login and apply via your bank account by selecting the IBL Finance IPO in the Invest section. The other option you can apply IBL Finance IPO via IPO forms download via the NSE website. Check out the IBL Finance forms – click NSE IPO Forms download, fill and submit in your bank or with your broker.

IBL Finance Company Financial Report

₹ in Crores
Year	Revenue	Expense	PAT
2021	₹1.13	₹1.22	₹0.10
2022	₹3.27	₹2.71	₹0.43
2023	₹13.33	₹10.59	₹1.93

IBL Finance IPO Valuation – FY2023

Check IBL Finance IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.

Earning Per Share (EPS):	₹2.56 per Equity Share
Price/Earning P/E Ratio:	N/A
Return on Net Worth (RoNW):	9.41%
Net Asset Value (NAV):	₹12.20 per Equity Share

Peer Group

MAS Financial Services Limited
Arman Financial Service Limited
Apollo Finvest (India) Limited
CSL Finance Limited
Ugro Capital Limited

Company Promoters

Manish Patel
Piyush Patel
Mansukhbhai Patel

IBL Finance IPO Registrar

Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: ipo@bigshareonline.com
Website: https://linkintime.co.in/

IBL Finance IPO Allotment Status

Check IBL Finance IPO allotment status on Linktime website URL. Click Here

IBL Finance IPO Lead Managers aka Merchant Bankers

Fedex Securities Pvt Ltd

Company Address

IBL Finance Limited
Shop-151, Silver Stone Arcade, Near.
Kantheriya Hanuman Temple, OP-34/A+B+C+D, FP-50,
Singanpore, Causeway Road, Katargam, Surat- 395004
Phone: 9828116900
Email: compliance@iblfinance.in
Website: https://iblfinance.in/

IBL Finance IPO FAQs

What is IBL Finance IPO?

IBL Finance IPO is an NSE SME IPO. They are going to raise ₹34.30 Crores via IPO. The issue is priced at ₹51 per equity share. The IPO is to be listed on NSE.

When IBL Finance IPO will open?

The IPO is to open on January 9, 2024 for QIB, NII, and Retail Investors.

What is IBL Finance IPO Investors Portion?

The investors’ portion for NII is 50%, and Retail is 50%.

How to Apply the IBL Finance IPO?

You can apply IBL Finance IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

How to Apply the IBL Finance IPO through Zerodha?

Log in to Console in Zerodha Website or in Application. Go to Portfolio and Click on IPO. You will see the IPO Name “IBL Finance”. Click on Bid Button. Enter your UPI ID, Quantity, and Price. Submit IPO Application Form. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Zerodha.

How to Apply the IBL Finance IPO through Upstox?

Log in to Upstox Application with your credentials. Select the IPO. You will see the IPO Name “IBL Finance”. Click on Bid Button. Confirm your application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Upstox.

How to Apply the IBL Finance IPO through Paytm Money?

Log in to Paytm Money Application with your credentials. Select the IPO. You will see the IPO Name “IBL Finance”. Click on Bid Button. Confirm your application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Paytm Money.

What is IBL Finance IPO Size?

IBL Finance IPO size is ₹34.30 crores.

What is IBL Finance IPO Price Band?

IBL Finance IPO Price Band is ₹51 per equity share.

What is IBL Finance IPO Minimum and Maximum Lot Size?

The IPO bid is 2000 shares with ₹102,000.

What is IBL Finance IPO Allotment Date?

IBL Finance IPO allotment date is January 12, 2024.

What is IBL Finance IPO Listing Date?

IBL Finance IPO listing date is January 16, 2024. The IPO to list on NSE SME.

Note: The IBL Finance IPO details are announced officially. The IPO grey market premium (IBL Finance IPO Premium) is updated on the respective page. You can check our IPO grey market page for daily updates.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.